NBTX
NanobiotixNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.61B
P/E Ratio
—
EPS
$-0.59
Beta
0.55
52W High
$41.89
52W Low
$3.26
50-Day MA
$31.31
200-Day MA
$20.59
Dividend Yield
—
Profit Margin
-73.50%
Forward P/E
56.50
PEG Ratio
—
About Nanobiotix
Nanobiotix SA, a clinical-stage biotechnology, is focused on the development of candidate products for the treatment of cancer. The company is headquartered in Paris, France.
Fundamentals
| Revenue (TTM) | $32.59M |
| Gross Profit (TTM) | $32.59M |
| EBITDA | $-10.49M |
| Operating Margin | -196.40% |
| Return on Equity | -198.70% |
| Return on Assets | -10.10% |
| Revenue/Share (TTM) | $0.68 |
| Book Value | $-2.04 |
| Price-to-Book | 65.02 |
| Price-to-Sales (TTM) | 49.28 |
| EV/Revenue | 47.83 |
| EV/EBITDA | -2.45 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 186.80% |
| Shares Outstanding | $48.50M |
| Float | $31.07M |
| % Insiders | 0.00% |
| % Institutions | 11.79% |
Historical Volatility
HV 10-Day
59.30%
HV 20-Day
76.58%
HV 30-Day
75.64%
HV 60-Day
96.70%
HV Rank
35.7%
Volatility is currently contracting
Analyst Ratings
Consensus ($33.19 target)
6
BuyData last updated: 4/29/2026